<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893737</url>
  </required_header>
  <id_info>
    <org_study_id>110211</org_study_id>
    <nct_id>NCT00893737</nct_id>
  </id_info>
  <brief_title>&quot;Completeness of Response&quot; Following Treatment With Treximet™ for Migraine</brief_title>
  <official_title>An Open-label Study to Evaluate &quot;Completeness of Response&quot; Following Treatment With Treximet™ for Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cady, Roger, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cady, Roger, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many clinical trials may not fully explore criteria that are important to some migraine
      patients' definition of &quot;complete response.&quot; This study offers the opportunity to evaluate
      the effectiveness of Treximet™ when non-standard criteria are examined (for example, neck
      pain, irritability or fatigue). Subjects enrolled at 8 investigative sites will complete 2
      visits. Subjects will complete a Completeness of Response Survey at Visit 1 considering their
      usual migraine medication (a triptan) and a Completeness of Response Survey at Visit 2
      considering their study medication (Treximet™).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the screening visit (Visit 1), following written informed consent, subjects will provide a
      medical, medication and migraine history. A physical and neurological exam and pregnancy test
      (if appropriate) will be performed. Vital signs will be recorded for all subjects. The
      Headache Impact Test (HIT-6) and Baseline Patient Perception of Migraine Questionnaire
      (PPMQ-R) will be completed with the Baseline Completeness of Response Survey (CORS)
      considering migraine therapy (triptan) utilized during the 3 months prior to enrollment. The
      Completeness of Response Survey will collect traditional and non-traditional symptoms.
      Subjects are instructed to treat all migraines that occur in the next 2 months. Subjects will
      treat with a single tablet of Treximet™ as soon as they have a headache indicative of
      migraine and are encouraged to treat when the headache is mild. A Headache Diary documenting
      onset of headache pain and associated symptoms, time of treatment with study medication,
      symptoms at 2 hours following treatment, time of relief, recurrence of symptoms within 24
      hours post-treatment, and adverse events will be dispensed with study medication. Subjects
      may take a 2nd dose of study medication or medication determined by the investigator for
      rescue of persistent or recurring headache at 2 or more hours following the 1st dose of study
      medication. Alternate rescue medication can be provided at the discretion of the investigator
      but may not include triptan, non-steroidal anti-inflammatory (short-acting NSAID between 6
      hours before and 2 hours after study medication or long-acting NSAID between 24 hours before
      and 24 hours after study medication), or ergotamine-containing or ergot-type medication.
      Subjects must be headache-free for 24 hours before recording the onset of a &quot;new&quot; migraine
      attack. The study coordinator will contact subjects at Month 1 to verify treatment and diary
      compliance.

      At Visit 2, following 2 months of treatment with Treximet™, the subject will return to the
      study site and return completed Headache Diaries. The End of Study CORS, CORS Comparator and
      End of Study PPMQ-R will be completed considering response with study medication. Adverse
      events will be documented and Diaries and Questionnaires will be reviewed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Scores From Completeness of Response Survey (CORS)</measure>
    <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
    <description>CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.
The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan</measure>
    <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
    <description>CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)</measure>
    <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
    <description>Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Treximet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)</intervention_name>
    <description>Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.</description>
    <arm_group_label>Treximet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject must be/have

          -  age 18 to 65

          -  able to read, understand, and sign informed consent

          -  willing to record migraine headaches and response to treatment in diary

          -  diagnosis of migraine headache (IHS 1.1 or 1.2), without and/or with aura

          -  at least one year history of migraine

          -  3-8 attacks per month in past 3 months

          -  onset of migraine before age 50

          -  current triptan user (treated with triptan as primary migraine therapy at least 2
             times per month in 3 months prior to screening)

          -  history of migraine starting at mild pain for at least 75% of migraine attacks

          -  use reliable method of birth control if female and childbearing potential (i.e.
             reliable barrier method, oral contraceptive, implant, contraceptive patch, long term
             injectable contraceptive, intrauterine device or tubal ligation)

          -  on stabilized dosages of current concomitant medications at least 90 days (may include
             migraine preventive medications), and willing to continue during study period

        Exclusion Criteria:

        Subject has/is

          -  history of serotonin syndrome

          -  medical condition that, in opinion of the investigator, could confound results of the
             study

          -  female of childbearing potential not using adequate contraceptive measures

          -  15 or more headache days per month in total, or history of retinal,, basilar or
             hemiplegic migraine, cluster headache, or secondary headaches (such as due to trauma,
             infection, alterations of homeostasis, ENT or psychiatric disorders, cranial or
             cervical disorders or neuralgias)

          -  in investigator's opinion, is likely to have unrecognized cardiovascular or
             cerebrovascular disease (based on history or presence of risk factors including but
             not limited to, hypertension, hypercholesterolemia, smoker, obesity, diabetes, or
             family history of coronary artery disease)

          -  blood pressure ≥ 140/90 mmHg in 2 of 3 BP measurements at screening or is taking any
             angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker

          -  a history of congenital heart disease, cardiac arrhythmias requiring medication, or
             history of clinically significant electrocardiogram abnormality that, in
             investigator's opinion, contraindicates participation in this study

          -  evidence or history of ischemic vascular disease including: ischemic heart disease,
             ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome, or
             signs/symptoms consistent with any of above

          -  evidence or history of central nervous system pathology including stroke and/or
             transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower
             convulsive threshold; or has been treated with antiepileptic drug for seizure control
             within 5 years prior to screening

          -  history of impaired hepatic or renal function that, in investigator's opinion,
             contraindicates participation in study

          -  hypersensitivity, intolerance, or contraindication to use of any triptan, NSAID or
             aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps and
             asthma

          -  currently taking, or has taken in previous three months, migraine prophylactic
             medication containing methysergide; or is taking migraine or menstrual migraine
             prophylactic medication that is not stabilized (i.e., change of dose within the past 2
             months)

          -  recent history of regular use of opioids or barbiturates for treatment of migraine
             headache and/or other non-migraine pain (regular use defined as an average of 4 days
             per month over last 6 months)

          -  taken, or plans to take, a monoamine oxidase inhibitor (MAOI), including herbal
             preparations containing St. John's Wort (Hypericum perforatum), anytime within 2 weeks
             prior to screening through 2 weeks post final study treatment

          -  history of any bleeding disorder or is currently taking anti-coagulant or antiplatelet
             agent

          -  evidence or history of gastrointestinal surgery or GI ulceration or perforation in
             past six months, gastrointestinal bleeding in past year; or evidence or history of
             inflammatory bowel disease

          -  pregnant, actively trying to become pregnant, or breast feeding

          -  evidence of alcohol or substance abuse within last year or any concurrent medical or
             psychiatric condition which, in investigator's judgment, will likely interfere with
             study conduct, subject cooperation, or evaluation and interpretation of study results,
             or which otherwise contraindicates participation in this clinical trial

          -  participated in an investigational drug trial within previous four weeks or plans to
             participate in another study at any time during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger K Cady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinvest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westside Family Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinvest</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research/Ryan Headache Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neurological Associates, PC</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Headache Clinic and Research Center</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Headache Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005 Sep;45(8):983-91.</citation>
    <PMID>16109111</PMID>
  </reference>
  <reference>
    <citation>Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4;297(13):1443-54.</citation>
    <PMID>17405970</PMID>
  </reference>
  <reference>
    <citation>Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62. Erratum in: Neurology 2000 Jan 9;56(1):142.</citation>
    <PMID>10993991</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <results_first_submitted>September 22, 2010</results_first_submitted>
  <results_first_submitted_qc>January 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2011</results_first_posted>
  <last_update_submitted>January 4, 2011</last_update_submitted>
  <last_update_submitted_qc>January 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Roger K. Cady, MD</name_title>
    <organization>Clinvest</organization>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Headache, Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Patient In 6/2/09 Last Patient In 7/17/09 Patients enrolled at 5 Headache Specialty clinics, 2 Primary Care practices, and 1 Neurological practice.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treximet</title>
          <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treximet</title>
          <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan</title>
        <description>CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours.</description>
        <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Reporting Treximet Provides Therapeutic Advantage Over Usual Pre-study Triptan</title>
          <description>CORS completed at Visit 1 regarding participant pre-study triptan and at Visit 2 regarding Treximet taken in study. Areas of therapeutic advantage evaluated: How often does 1 dose completely relieve (1) headache pain (2) neck/shoulder pain (3) nausea (4) light sensitivity (5) sound sensitivity (6) irritability. How quickly can/do you (1) concentrate or think clearly (2) resume normal activities (3) function normally (4) feel completely normal. How confident are you that (1) one dose will completely relieve migraine within 2 hours (2) once relieved, migraine will not return within 24 hours.</description>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>How often 1 dose relieves headache pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How often 1 dose relieves neck/shoulder pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How often 1 dose relieves nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How often 1 dose relieves light sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How often 1 dose relieves sound sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How often 1 dose relieves irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How quickly can you concentrate or think clearly</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How quickly can you resume normal activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How quickly can you function normally</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>How quickly do you feel completely normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confidence 1 dose will relieve migraine in 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confidence migraine will not return in 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)</title>
        <description>Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction.</description>
        <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Paired T-test Indicating Greater Subject Satisfaction With Treximet Over Usual Pre-study Triptan as Determined by the Revised Patient Perception of Migraine Questionnaire (PPMQ-R)</title>
          <description>Scores calculated for (1) Efficacy (2) Functionality (3) Ease of use (4) Cost. Higher score represents better treatment satisfaction.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.61" lower_limit="4.64" upper_limit="12.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functionality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" lower_limit="9.39" upper_limit="18.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="-0.11" upper_limit="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.28" lower_limit="1.83" upper_limit="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Scores From Completeness of Response Survey (CORS)</title>
        <description>CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.
The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication).</description>
        <time_frame>Visit 1 (screening) and Visit 2 (study completion following 2-month treatment period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treximet</title>
            <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Scores From Completeness of Response Survey (CORS)</title>
          <description>CORS scores for Pain (0-4), Associated Symptoms (0-4), Limbic/Affective Symptoms (0-5), and Speed of Return to Functionality (1-5), represent outcome measures that are relevant to patients. Higher scores represent better treatment efficacy.
The analysis compares CORS scores for usual triptan (pre-study) versus (vs.) Treximet (study medication).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.03" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associated Symptoms Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.09" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limbic Symptoms Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.12" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Functionality Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.05" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treximet</title>
          <description>Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Verbatim Response</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine without aura</sub_title>
                <description>without intractable headache, but with Status Migrainosus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>Verbatim Response</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Tightness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Jittery</sub_title>
                <counts group_id="E1" events="19" subjects_affected="3" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Light Headed</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sleepy</sub_title>
                <counts group_id="E1" events="21" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Tired</sub_title>
                <counts group_id="E1" events="14" subjects_affected="4" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of Results is specifically authorized, subject to the provisions of STUDY AGREEMENT. INVESTIGATOR is free to publish Results of its part of study in collaboration with other investigators, but in compliance with confidentiality agreement and subsequent to full study publication issued by CLINVEST. INVESTIGATOR agrees to submit a copy of any results communication to CLINVEST for review and comment 60 days prior to submission for publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rebecca Browning</name_or_title>
      <organization>Clinvest</organization>
      <phone>(417) 841-3664</phone>
      <email>rbrowning@clinvest.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

